Suzhou MedicalSystem Technology Balans Gezondheid

Financiële gezondheid criteriumcontroles 0/6

Suzhou MedicalSystem Technology heeft een totaal eigen vermogen van CN¥921.0M en een totale schuld van CN¥830.6M, wat de schuld-eigenvermogensverhouding op 90.2% brengt. De totale activa en totale passiva bedragen respectievelijk CN¥3.3B en CN¥2.4B.

Belangrijke informatie

90.2%

Verhouding schuld/eigen vermogen

CN¥830.60m

Schuld

Rente dekkingsratio	n/a
Contant	CN¥194.79m
Aandelen	CN¥920.98m
Totaal verplichtingen	CN¥2.39b
Totaal activa	CN¥3.31b

Recente financiële gezondheidsupdates

Geen updates

Recent updates

Suzhou MedicalSystem Technology Co., Ltd. (SHSE:603990) Held Back By Insufficient Growth Even After Shares Climb 29%

Oct 01

Suzhou MedicalSystem Technology Co., Ltd.'s (SHSE:603990) Subdued P/S Might Signal An Opportunity

Jun 26

Suzhou MedicalSystem Technology Co., Ltd.'s (SHSE:603990) Shares Leap 30% Yet They're Still Not Telling The Full Story

Mar 08

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( CN¥604.2M ) van 603990 } dekken niet de korte termijn passiva ( CN¥1.5B ).

Langlopende schulden: De kortetermijnactiva van 603990 ( CN¥604.2M ) dekken de langetermijnschulden ( CN¥891.7M ) niet.

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: De netto schuld/eigen vermogen ratio ( 69% ) 603990 wordt als hoog beschouwd.

Schuld verminderen: De schuld/eigen vermogen-ratio van 603990 is de afgelopen 5 jaar gestegen van 28.8% naar 90.2%.

Schuldendekking: De operationele kasstroom van 603990 is negatief, waardoor de schuld niet goed gedekt is.

Rentedekking: Er zijn onvoldoende gegevens om te bepalen of de rentebetalingen van 603990 op haar schulden goed worden gedekt door EBIT.

Suzhou MedicalSystem Technology Balans Gezondheid

Financiële gezondheid criteriumcontroles 0/6

Belangrijke informatie

Recente financiële gezondheidsupdates

Recent updates

Third quarter 2024 earnings released: CN¥0.30 loss per share (vs CN¥0.075 loss in 3Q 2023)

Suzhou MedicalSystem Technology Co., Ltd. (SHSE:603990) Held Back By Insufficient Growth Even After Shares Climb 29%

Suzhou MedicalSystem Technology Co., Ltd. to Report Q3, 2024 Results on Oct 31, 2024

New minor risk - Share price stability

Second quarter 2024 earnings released: CN¥0.31 loss per share (vs CN¥0.26 loss in 2Q 2023)

New major risk - Revenue and earnings growth

Suzhou MedicalSystem Technology Co., Ltd. to Report First Half, 2024 Results on Aug 10, 2024

Suzhou MedicalSystem Technology Co., Ltd.'s (SHSE:603990) Subdued P/S Might Signal An Opportunity

First quarter 2024 earnings released: EPS: CN¥0.03 (vs CN¥0.038 loss in 1Q 2023)

Suzhou MedicalSystem Technology Co., Ltd., Annual General Meeting, May 20, 2024

Suzhou MedicalSystem Technology Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024

Suzhou MedicalSystem Technology Co., Ltd.'s (SHSE:603990) Shares Leap 30% Yet They're Still Not Telling The Full Story

Suzhou MedicalSystem Technology Co., Ltd. (SHSE:603990) announces an Equity Buyback for CNY 30 million worth of its shares.

Suzhou MedicalSystem Technology Co., Ltd. to Report Fiscal Year 2023 Results on Apr 30, 2024

Third quarter 2023 earnings released: CN¥0.075 loss per share (vs CN¥0.008 loss in 3Q 2022)

Second quarter 2023 earnings released: CN¥0.26 loss per share (vs CN¥0.041 profit in 2Q 2022)

Suzhou MedicalSystem Technology Co., Ltd. to Report First Half, 2023 Results on Aug 18, 2023

First quarter 2023 earnings released: CN¥0.05 loss per share (vs CN¥0.046 profit in 1Q 2022)

Third quarter 2022 earnings released: CN¥0.011 loss per share (vs CN¥0.012 loss in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.054 (vs CN¥0.046 in 2Q 2021)

Investor sentiment deteriorated over the past week

Mianyang Haoxiang Holdings Co., Ltd agreed to acquire an unknown minority stake in Suzhou MedicalSystem Technology Co., Ltd. (SHSE:603990) from Weng Kang, Yan Huanghong, Wang Jianhua and Fu Hong for approximately CNY 340 million.

Suzhou MedicalSystem Technology Co., Ltd. announced that it expects to receive CNY 238.92928 million in funding from Mianyang Haoxiang Holdings Co., Ltd

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Less than half of directors are independent

Investor sentiment deteriorated over the past week

Now 24% undervalued

Now 22% undervalued

Now 21% undervalued

Second quarter 2021 earnings released: EPS CN¥0.06 (vs CN¥0.06 in 2Q 2020)

Investor sentiment deteriorated over the past week

First quarter 2021 earnings released: EPS CN¥0.04 (vs CN¥0.12 loss in 1Q 2020)

New 90-day low: CN¥29.95

New 90-day low: CN¥30.70

New 90-day low: CN¥31.00

New 90-day low: CN¥37.65

Suzhou MedicalSystem Technology Co., Ltd. (SHSE:603990) signed an agreement to acquire remaining 49% stake in Haikou Mary Hospital Co., Ltd.

Third quarter earnings released

Suzhou MedicalSystem Technology Co., Ltd. to Report Q3, 2020 Results on Oct 30, 2020

New 90-day low: CN¥41.30

Suzhou MedicalSystem Technology Co., Ltd. (SHSE:603990) signed an equity acquisition intention agreement to acquire 51% stake in Heilongjiang Tianyuan Obstetrics and Gynecology Hospital Co., Ltd. from Tibet Daming Investment Management Co., Ltd. and Xue Weiwei for approximately CNY 170 million.

Suzhou MedicalSystem Technology Co., Ltd. (SHSE:603990) signed a letter of intent to acquire 51% stake in a Hospital located in Heilongjiang for approximately CNY 170 million.

Earnings released

Zhongruo (Suzhou) Asset Management Co., Ltd. completed the acquisition of 5.34% stake in Suzhou MedicalSystem Technology Co., Ltd. (SHSE:603990) from Hangzhou Anshi Investment Management Partnership Enterprise (Limited Partnership).

Analyse van de financiële positie

Schuld/ eigen vermogen geschiedenis en analyse

Balans

Ontdek gezonde bedrijven